16209-00-0

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(1H-Pyrazol-1-yl)benzoic acid is used as a key intermediate in the synthesis of pharmaceuticals for its potential biological activities, including anti-inflammatory and anticancer properties. Its unique structure allows for the development of new drugs with improved therapeutic effects.
Used in Agrochemical Synthesis:
In the agrochemical industry, 4-(1H-Pyrazol-1-yl)benzoic acid is utilized as a building block in the preparation of various agrochemicals, contributing to the development of effective and environmentally friendly products for crop protection and pest control.
Used in Organic Compound Preparation:
4-(1H-Pyrazol-1-yl)benzoic acid serves as a versatile starting material for the synthesis of diverse organic compounds, enabling the creation of new molecules with potential applications in various fields, such as materials science, catalysis, and medicinal chemistry.

InChI:InChI=1/C10H8N2O2/c13-10(14)8-2-4-9(5-3-8)12-7-1-6-11-12/h1-7H,(H,13,14)/p-1

Upstream product

• 400750-29-0 methyl 4-(1H-pyrazol-1-yI)benzenecarboxylate 
• 25699-83-6 4-pyrazol-1-yl-benzonitrile 
• 1194-02-1 4-fluorobenzonitrile 
• 403-33-8 methyl 4-flurobenzoate 

Downstream Products

• 143426-47-5 4-pyrazol-1-yl-benzoic acid ethyl ester 
• 1353548-25-0 [(Sn(n-Bu)2)4(4-pyrazolylbenzoate)2O₂(MeO)2] 
• 1087329-20-1 (R)-tert-butyl 3-(4-(1H-pyrazol-1-yl)benzamido)pyrrolidine-1-carboxylate 
• 1087329-24-5 N-methyl-4-(1H-pyrazol-1-yl)-N-[(3R)-pyrrolidin-3-yl]benzamide 

Relevant academic research and scientific papers

Diphenyl ether-containing 4-(1H-pyrazol-1-yl)biphenylformamide compounds and applications

The present invention discloses diphenyl ether-containing 4- (1H- pyrazol-1-yl) biphenylformamide compounds and applications, the structural formula is: wherein the R group is: 4-H, 4-Cl, 2-Cl and4-OCH3 of one. The application of diphenyl ether

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5′ and R6 are described herein.

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, X1, X2, m, and n are described herein.

Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists

On the basis of the previously reported benzimidazole 1,3′- bipyrrolidine benzamides (1), a series of related pyrrolidin-3-yl-N- methylbenzamides were synthesized and evaluated as H3 receptor antagonists. In particular, compound 32 exhibits pot

AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor

Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

FIBROSIS INHIBITOR

Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2):(1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms:(2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

Pyrrole derivatives

Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, an optionally substituted C1-C4 alkylene, etc.; Ar2 is an optionally substituted aryl, etc.; W2 and Ar1 mean the following (1) and (2): (1) W1 is an optionally substituted C1-C4 alkylene, etc.; Ar1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is an optionally substituted C2-C5 alkylene, an optionally substituted C2-C5 alkenylene, etc.; and Ar1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.